RNAimmune, a biotech company focused on developing groundbreaking mRNA therapies, received approval from the U.S. FDA to begin Phase 1 clinical studies for an investigational new drug (IND).
RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines